Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Reshape Lifesciences Inc (NQ: RSLS ) 5.600 +0.220 (+4.09%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Reshape Lifesciences Inc < Previous 1 2 3 Next > ReShape Lifesciences Announces 1-for-58 Reverse Stock Split September 19, 2024 Effective as of Commencement of Trading on September 23, 2024 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update August 14, 2024 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update August 13, 2024 Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024 From ReShape Lifesciences Inc Via GlobeNewswire SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHUY, RSLS on Behalf of Shareholders July 19, 2024 From Halper Sadeh LLC Via GlobeNewswire RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS July 16, 2024 From Kahn Swick & Foti, LLC Via Business Wire RSLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ReShape Lifesciences Inc. Is Fair to Shareholders July 15, 2024 From Halper Sadeh LLC Via Business Wire ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys July 09, 2024 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update May 15, 2024 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update May 14, 2024 Conference Call to be Held at 4:30 pm ET on Wednesday, May 15, 2024 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update April 01, 2024 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System March 28, 2024 Patent Significantly Strengthens Intellectual Property Portfolio From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX March 04, 2024 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX February 22, 2024 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX January 24, 2024 First Time Introduction of Lap-Band® 2.0 FLEX to the Next Generation of Surgeons From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives December 20, 2023 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX December 12, 2023 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds November 21, 2023 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan November 08, 2023 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update November 06, 2023 Conference Call to be Held at 5:00 pm ET on Wednesday, November 8, 2023 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering September 29, 2023 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI September 22, 2023 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System September 21, 2023 Royalty-Bearing License Agreement Covers the Countries in the Indian Subcontinent, Representing Approximately 20% to 25% of the World’s Population From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System September 19, 2023 Granted One Patent from USPTO and Receives Two Notices of Allowance, Providing Foundational Protection From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device September 14, 2023 $331,541 Grant will Explore the use of High-Resolution Endoscopic Ultrasound to Aid in the Placement of the DBSN™ Device From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update August 07, 2023 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update August 03, 2023 Conference Call to be Held at 5:00 pm ET on Monday, August 7, 2023 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software June 29, 2023 Hive’s AI- and SMS-based Patient-Self-Service Technology to Manage Prospective Lap-Band® Leads From Initial Contact Through Surgical Consultation From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting June 28, 2023 From ReShape Lifesciences Inc Via GlobeNewswire ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0 June 26, 2023 Enhanced Band Reservoir Technology Designed to Improve the Patient Experience From ReShape Lifesciences Inc Via GlobeNewswire Life Science Investor Forum: Presentations Now Available for Online Viewing June 23, 2023 Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
